Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research report report published on Friday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

A number of other brokerages have also commented on URGN. Guggenheim reaffirmed a “buy” rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Friday, June 13th. Piper Sandler started coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Urogen Pharma Stock Performance

Shares of URGN opened at $17.40 on Friday. The company has a 50-day simple moving average of $19.00 and a 200-day simple moving average of $13.69. The firm has a market capitalization of $804.92 million, a P/E ratio of -5.24 and a beta of 1.00. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, equities analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the sale, the general counsel directly owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,062 shares of company stock worth $465,115 over the last three months. 4.70% of the stock is owned by insiders.

Institutional Trading of Urogen Pharma

Several hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Urogen Pharma during the first quarter valued at approximately $35,461,000. Soleus Capital Management L.P. bought a new stake in shares of Urogen Pharma during the second quarter valued at approximately $29,934,000. Vestal Point Capital LP grew its stake in shares of Urogen Pharma by 32.1% during the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after purchasing an additional 522,957 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Urogen Pharma by 607.1% during the second quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock valued at $15,742,000 after purchasing an additional 986,567 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.